Comparison of diagnostic accuracy of endometrial curettage and aspiration biopsy in patients with endometrial hyperplasia

Comparison of diagnostic accuracy of endometrial curettage and aspiration biopsy in patients with endometrial hyperplasia treated with progesterone

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221008056114N1

Enrollment

Registered

2022-11-22

Start date

2022-12-06

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial hyperplasia. Endometrial hyperplasia

Interventions

Intervention group: Medroxyprogesterone tablets 20 mg daily for 15 days to 3 months are placed (with any treatment regimen). After 4 weeks of treatment, endometrial samples will be taken from each pat

Eligibility

Sex/Gender

Female

Age

18 Years to 47 Years

Inclusion criteria

Inclusion criteria: Age 18 to 47 years Diagnosis of uterine hyperplasia with AUB Absence of focal lesion

Exclusion criteria

Exclusion criteria: The patient's unwillingness to participate in the study Improper use of medication Presence of focal endometrial lesion Patient willingness to hysterectomy

Design outcomes

Primary

Measure	Time frame
Uterine hyperplasia. Timepoint: Before treatment. Method of measurement: Curtage.	—

Secondary

Measure	Time frame
Endometrial hyperplasia. Timepoint: Three months after treatment. Method of measurement: Sampling of the endometrium and comparison of pathologies.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBahar Gholamnia

Qazvin University of Medical Sciences

bahar.gholamnia@ymail.com+98 28 3333 6001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026